Biobetters From an Integrated Computational/Experimental Approach

Computational and Structural Biotechnology Journal

Volumn 15, Issue , 2017, Pages 138-145

  Kuyucak, Serdar ^a   Kayser, Veysel ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Docking; Free energy perturbation; Molecular dynamics; Potential of mean force; Rational drug design

Indexed keywords

COMPUTATIONAL CHEMISTRY; DISEASES; EPITOPES; FREE ENERGY; INVERSE PROBLEMS; MONOCLONAL ANTIBODIES; PEPTIDES;

AUTOIMMUNE DISEASE; DESIGN PROBLEMS; DOCKING; EXPERIMENTAL APPROACHES; FREE ENERGY PERTURBATION; MOST LIKELY; POTENTIAL OF MEAN FORCE; PROPERTY; PROTEIN BASED THERAPEUTICS; RATIONAL DRUG DESIGNS;

MOLECULAR DYNAMICS;

BIOBETTER; LIGAND; MONOCLONAL ANTIBODY; NEW DRUG; POTASSIUM CHANNEL; PROTEIN; PROTEIN AGGREGATE; UNCLASSIFIED DRUG;

BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DISSOCIATION CONSTANT; DRUG DESIGN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MASS SPECTROMETRY; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

EID: 85010460349     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.1016/j.csbj.2017.01.003     Document Type: Review

References (73)

1. [1] Alonso, H., Bliznyuk, A.A., Gready, J.E., Combining docking and molecular dynamic simulations in drug design. Med Res Rev 26 (2006), 531–568.
2. [2] Gordon, D., Chen, R., Chung, S.H., Computational methods of studying the binding of toxins from venomous animals to biological ion channels. Physiol Rev 93 (2013), 767–802.
3. [3] Kuyucak, S., Norton, R.S., Computational approaches for designing potent and selective analogues of peptide toxins as novel therapeutics. Future Med Chem 6 (2014), 1645–1658.
4. [4] Halperin, I., Ma, B., Wolfson, H., Nussinov, R., Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins 47 (2002), 409–443.
5. [5] Brooijmans, N., Kuntz, I.D., Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 32 (2003), 335–373.
6. [6] Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., et al. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19 (1998), 1639–1662.
7. [7] Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30 (2009), 2785–2791.
8. [8] Mintseris, J., Pierce, B., Wiehe, K., Anderson, R., Chen, R., Weng, Z., Integrating statistical pair potentials into protein complex prediction. Proteins 69 (2007), 511–520.
9. [9] Dominguez, C., Boelens, R., Bonvin, A.M., HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125 (2003), 1731–1737.
10. [10] De Vries, S.J., van Dijk, A.D., Krzeminski, M., van Dijk, M., Thureau, A., Hsu, V., et al. HADDOCK versus HADDOCK: new features and performance of HADDOCK2.0 on the CAPRI targets. Proteins 69 (2007), 726–733.
11. [11] Warren, G.L., Andrews, C.W., Capelli, A.M., Clarke, B., LaLonde, J., Lambert, M.H., et al. A critical assessment of docking programs and scoring functions. J Med Chem 49 (2006), 5912–5931.
12. [12] Patra, S.M., Bastug, T., Kuyucak, S., Binding of organic cations to gramicidin: a channel studied with autodock and molecular dynamics simulations. J Phys Chem B 111 (2007), 11303–11311.
13. [13] Ander, M., Luzhkov, V.B., Aqvist, J., Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state–docking and computer simulations of a homology model. Biophys J 9 (2007), 820–831.
14. [14] Yi, H., Qiu, S., Cao, Z.J., Wu, Y.L., Li, W.X., Molecular basis of inhibitory peptide maurotoxin recognizing Kv1.2 channel explored by ZDOCK and molecular dynamic simulations. Proteins 70 (2008), 844–854.
15. [15] Chen, P.C., Kuyucak, S., Mechanism and energetics of charybdotoxin unbinding from a potassium channel from molecular dynamics simulations. Biophys J 96 (2009), 2577–2588.
16. [16] Chen, P.C., Kuyucak, S., Developing a comparative docking protocol for the prediction of peptide selectivity profiles: investigation of potassium channel toxins. Toxins 4 (2012), 110–138.
17. [17] Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., et al. Scalable molecular dynamics with NAMD. J Comput Chem 26 (2005), 1781–1802.
18. [18] Humphrey, W., Dalke, A., Schulten, K., VMD–visual molecular dynamics. J Mol Graph 14 (1996), 33–38.
19. [19] MacKerell, A.D., Bashford, D., Bellott, M., Dunbrack, R.L., Evanseck, J.D., Field, M.J., et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 30 (1998), 3586–3616.
20. [20] Frenkel, D., Smit, B., Understanding molecular simulation: from algorithms to applications. 1996, Academic Press, San Diego.
21. [21] Leach, A.R., Molecular Modelling, principles, applications. 2001, Prentice Hall, New York.
22. [22] Stansfeld, P.J., Sansom, M.S.P., Molecular simulation approaches to membrane proteins. Structure 19 (2011), 1562–1572.
23. [23] Dror, R.O., Dirks, R.M., Grossman, J.P., Xu, H., Shaw, D.E., Biomolecular simulations: a computational microscope for molecular biology. Annu Rev Biophys 41 (2012), 429–452.
24. [24] Bastug, T., Kuyucak, S., Molecular dynamics simulations of membrane proteins. Biophys Rev 4 (2012), 271–282.
25. [25] Bastug, T., Kuyucak, S., Importance of the peptide backbone description in modeling the selectivity filter in potassium channels. Biophys J 96 (2009), 4006–4012.
26. [26] Kollman, P.A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., et al. Calculating structures and free energies of complex molecules: combining molecular mechanic and continuum models. Acc Chem Res 33 (2000), 889–897.
27. [27] Zhou, H.X., Gilson, M.K., Theory of free energy and entropy in noncovalent binding. Chem Rev 109 (2009), 4092–4107.
28. [28] Deng, Y., Roux, B., Computations of standard binding free energies with molecular dynamics simulations. J Phys Chem B 113 (2009), 2234–2246.
29. [29] Christ, C.D., Mark, A.E., van Gunsteren, W.F., Basic ingredients of free energy calculations. J Comput Chem 31 (2010), 1569–1582.
30. [30] Steinbrecher, T., Labahn, A., Towards accurate free energy calculations in ligand-protein binding studies. Curr Med Chem 17 (2010), 767–785.
31. [31] Enyedy, I.J., Egan, W.J., Can we use docking and scoring for hit-to-lead optimization?. J Comput Aided Mol Des 22 (2008), 161–168.
32. [32] Schneider, G., Virtual screening: an endless staircase?. Nat Rev Drug Discov 9 (2010), 273–276.
33. [33] Brown, S.P., Muchmore, S.W., Large scale application of high-throughput molecular mechanics with Poisson-Boltzmann surface area for routine physics-based scoring of protein-ligand complexes. J Med Chem 52 (2009), 3159–3165.
34. [34] Singh, N., Warshel, A., Absolute binding free energy calculations: on the accuracy of computational scoring of protein-ligand interactions. Proteins 78 (2010), 1705–17123.
35. [35] Michel, J., Essex, J.W., Prediction of protein-ligand affinity by free energy simulations: assumptions, pitfalls and expectations. J Comput Aided Mol Des 24 (2011), 639–658.
36. [36] Chodera, J.D., Mobley, D.L., Shirts, M.R., Dixon, R.W., Branson, K., Pande, V.S., Alchemical free energy methods for drug discovery: progress and challenges. Curr Opin Struct Biol 21 (2011), 150–160.
37. [37] Mobley, D.L., Klimov, P.V., Perspective: alchemical free energy calculations in drug discovery. J Chem Phys, 137, 2012, 230901.
38. [38] Kumar, S., Bouzida, S.D., Swensen, R.H., Kollman, P.A., Rosenberg, J.M., The weighted histogram analysis method for free-energy calculations on biomolecules. J Comput Chem 13 (1992), 1011–1021.
39. [39] Chen, P.C., Kuyucak, S., Accurate determination of the binding free energy for KcsA-charybdotoxin complex from the potential of mean force calculations. Biophys J 100 (2011), 2466–2474.
40. [40] Rashid, M.H., Mahdavi, S., Kuyucak, S., Computational studies of marine toxins targeting ion channels. Mar Drugs 11 (2013), 848–869.
41. [41] Park, S., Schulten, K., Calculating potentials of mean force from steered molecular dynamics simulations. J Chem Phys 120 (2004), 5946–5961.
42. [42] Bastug, T., Chen, P.C., Patra, S.M., Kuyucak, S., Potential of mean force calculations of ligand binding to ion channels from Jarzynski's equality and umbrella sampling. J Chem Phys 128 (2008), 104–112.
43. [43] Rashid, M.H., Heinzelmann, G., Huq, R., Tajhya, R.B., Chang, S.C., Chhabra, S., et al. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation. PLoS One, 8, 2013, e78712.
44. [44] Bobrovnik, S.A., Determination of antibody affinity by ELISA. Theory J Biochem Biophys Methods 57 (2003), 213–236.
45. [45] Olaru, A., Bala, C., Jaffrezic-Renault, N., Aboul-Enein, H.Y., Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis. Crit Rev Anal Chem 45 (2015), 97–105.
46. [46] Geuijen, C.A.W., Clijsters-van der Horst, M., Cox, F., Throsby, P.M.L. Rood, Jongeneelen, M.A., et al. Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery. J Immunol Methods 302 (2005), 68–77.
47. [47] Kumar, S., Wang, X., Singh, S.K., Identification and impact of aggregation-prone regions in proteins and therapeutic monoclonal antibodies, in aggregation of therapeutic proteins. 2010, John Wiley & Sons, 103–118.
48. [48] den Engelsman, J., Garidel, P., Smulders, R., Koll, H., Smith, B., Bassarab, S., et al. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28 (2011), 920–933.
49. [49] Gokarn, Y., Agarwal, S., Arthur, K., Bepperling, A., Day, E.S., Filoti, D., et al. Biophysical techniques for characterizing the higher order structure and interactions of monoclonal antibodies, in state-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization. American Chemical Society, (eds.) Volume 2. Biopharmaceutical characterization The NISTmAb case study, vol. 1201, 2015, 285–327.
50. [50] Lakowicz, J.R., Principles of fluorescence spectroscopy. 3rd ed., 2006, Springer, Maryland, USA.
51. [51] Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Trout, B.L., Tryptophan-tryptophan energy transfer and classification of tryptophan residues in proteins: therapeutic monoclonal antibody as a model. J Fluoresc 21 (2010), 275–288.
52. [52] Reshetnyak, Y.K., Andreev, O.A., Borejdo, J., Toptygin, D.D., Brand, L., Burstein, E.A., The identification of tryptophan residues responsible for ATP-induced increase in intrinsic fluorescence of myosin subfragment 1. J Biomol Struct Dyn 18 (2000), 113–125.
53. [53] Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Forrer, K., Trout, B.L., A screening tool for therapeutic monoclonal antibodies: identifying the most stable protein and its best formulation based on thioflavin T binding. Biotechnol J 7 (2012), 127–132.
54. [54] Attri, A.K., Minton, A.P., New methods for measuring macromolecular interactions in solution via static light scattering: basic methodology and application to nonassociating and self-associating proteins. Anal Biochem 337 (2005), 103–110.
55. [55] Kurganov, E.R.R.B.I., Dobrov, E.N., Kinetics of thermal aggregation of tobacco mosaic virus coat protein. Biochemistry (Mosc) 67 (2002), 525–533.
56. [56] Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Forrer, K., Trout, B.L., Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation. J Pharm Sci 100 (2011), 2526–2542.
57. + channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 108 (2008), 1744–1773.
58. + conduction and selectivity. Science 280 (1998), 69–77.
59. [59] Chi, V., Pennington, M.W., Norton, R.S., Tarcha, E.J., Londono, L.M., Sims-Fahey, B., et al. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon 59 (2012), 529–546.
60. [60] Rashid, M.H., Kuyucak, S., Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations. J Phys Chem B 116 (2012), 4812–4822.
61. [61] Regaya, L., Beeton, C., Ferrat, G., Andreotti, N., Darbon, H., Waard, M. De, et al. Evidence for domain specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. J Biol Chem 279 (2004), 55690–55696.
62. [62] Rashid, M.H., Kuyucak, S., Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3/Kv1.1 selectivity. J Phys Chem B 118 (2014), 707–716.
63. [63] Rashid, M.H., Huq, R., Tanner, M., Chhabra, S., Khoo, K.K., Estrada, R., et al. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci Rep, 4, 2014, 4509.
64. [64] Jin, L., Boyd, B.J., Larson, I.C., Pennington, M.W., Norton, R.S., Nicolazzo, J.A., Enabling noninvasive systemic delivery of the Kv1.3-blocking peptide HsTX1[R14A] via the buccal mucosa. J Pharm Sci 105 (2016), 2173–2179.
65. [65] Clark, R.J., Akcan, M., Kaas, Q., Daly, N.L., Craik, D.J., Cyclization of conotoxins to improve their biopharmaceutical properties. Toxicon 59 (2012), 446–455.
66. [66] Dekan, Z., Vetter, I., Dally, N., Craik, D.J., Lewis, R.J., Alewood, P.F., α-Conotoxin ImI incorporating stable cystathionine bridges maintains full potency and identical three-dimensional structure. JACS 133 (2011), 15866–15869.
67. [67] Khoo, K.K., Wilson, M.J., Smith, B.J., Zhang, M.M., Gulyas, J., Yoshikami, D., et al. Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA. J Med Chem 54 (2011), 7558–7566.
68. [68] Chen, R., Lu, D.R., Xie, Z.L., Feng, J., Jia, Z., Ho, J., et al. Peptidomimetic star polymers for targeting biological ion channels. PLoS One, 11, 2016, e0152169.
69. [69] Ecker, D.M., Jones, S.D., Levine, H.L., The therapeutic monoclonal antibody market. MAbs 7 (2015), 9–14.
70. [70] Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., Kayser, V., The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev, 2016, 10.1016/j.addr.2016.11.004.
71. [71] Chennamsetty, N., Helk, B., Voynov, V., Kayser, V., Trout, B.L., Aggregation prone motifs in human immunoglobulin G. J Mol Biol 391 (2009), 404–413.
72. [72] Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B.L., Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 106 (2009), 11937–11942.
73. [73] Toofanny, R.D., Daggett, V., Understanding protein unfolding from molecular simulations. WIREs Comput Mol Sci 2 (2012), 405–423.